Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ipatasertib in Chinese Patients with Solid Tumors
NCT04341259Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipatasertib in solid tumor, sponsored by Roche. Primary endpoints: Area under the concentration-time curve from time zero to infinity up to 25 months, Area under the concentration-time curve from time zero to 24 hours and 6 more. Started Nov 2020; status: completed.
02
Drugs
ipatasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04341259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341259.